Novabay Pharmaceuticals (NBY) Q4 2025 earnings summary

Executive summary

• Completed a comprehensive business realignment in 2025, shifting from legacy pharmaceutical operations to a capital allocation strategy focused on acquiring and holding digital assets, primarily SKY tokens, to participate in decentralized financial networks.

• Divested major revenue-generating assets, including Avenova, PhaseOne, and DERMAdoctor, and exited the China NeutroPhase product line, with historical results now reported as discontinued operations.

• Raised significant capital through a January 2026 private placement ($137.4M in cash, stablecoins, and SKY tokens) and an at-the-market (ATM) equity program, supporting the new digital asset strategy.

Financial highlights

• Net loss from continuing operations was $33.2M for 2025, compared to $8.8M in 2024, primarily due to a $24.5M non-cash loss on warrant liabilities.

• Net income from discontinued operations was $11.1M in 2025, reflecting gains from asset divestitures.

• Cash and cash equivalents at year-end 2025 were $8.0M, with additional liquidity from subsequent financings.

• General and administrative expenses increased 3% year-over-year to $7.6M, mainly due to legal costs for strategic initiatives.

• Impairment charges of $854K were recorded for excess leased office capacity.

Outlook and guidance

• Management believes existing cash and equivalents, plus proceeds from the January 2026 private placement and ATM program, will fund planned operating expenses through at least March 2027.

• The company anticipates continued volatility in reported results due to digital asset market fluctuations and evolving accounting standards.